PR Newswire | Nov 10, 2020 07:01AM EST

Annual Meeting

11/10 06:00 CST

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting ROCKVILLE, Md., Nov. 10, 2020

ROCKVILLE, Md., Nov. 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV(r) Technology Platform, today announced that two oral presentations will be presented at the American Academy Ophthalmology (AAO) 2020 Annual Meeting, taking place November 13-15, 2020 in a virtual format.

The first presentation will feature data from the RGX-314 Phase I/II subretinal trial for the treatment of wet age-related macular degeneration (wet AMD). Details are as follows:

Title:Update on the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMDPresenter Dante Pieramici, M.D., Director, California Retina Research Foundation and Partner, California Retina ConsultantsDate/time:Available on-demand Session title: RET07 - Gene- and Cell-Based Therapies

The second presentation will include data from preclinical studies of suprachoroidal delivery of RGX-314. Details are as follows:

Title: Viral and Nonviral Suprachoroidal Ocular Gene TransferPresenter Peter A Campochiaro, M.D., Director, Retinal Cell and Molecular Laboratory, Professor of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of MedicineDate/time:Friday, November 13, 2020 at 12:36pm PSTSession title: RET07V - Gene- and Cell-Based Therapies

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia TruehartInvestor Relations and Corporate Communications347-926-7709ttruehart@regenxbio.com

Investors:Eleanor Barisser, 212-600-1902eleanor@argotpartners.com

Media:David Rosen, 212-600-1902david.rosen@argotpartners.com

View original content to download multimedia: http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2020-annual-meeting-301169240.html

SOURCE REGENXBIO Inc.